Floatz logo

Siplizumab

Anemia, Sickle Cell

Columbia Universitymonoclonal_antibodyPhase 1/2Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
89/ 100

Competitive context

134 Active assets in the Anemia, Sickle Cell cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB

View all 50 →

Same molecule, other indications

Siplizumab is also rated in:

lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
leukemiaDormant
CC
Indicative ·
42 / 100
View asset →
myelodysplastic syndromeDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →